
Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Epinephrine
Therapeutic Area : Immunology
Study Phase : Approved FDF
Recipient : Valeo Pharma
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Valeo Pharma Enters Into License Agreement with Kaléo for The Canadian Rights to Allerject®
Details : Under the Agreement, Valeo will be responsible for all commercial and medical activities for ALLERJECT (epinephrine) in Canada for an initial 10 years period.
Product Name : Allerject
Product Type : Hormone
Upfront Cash : Undisclosed
August 02, 2022
Lead Product(s) : Epinephrine
Therapeutic Area : Immunology
Highest Development Status : Approved FDF
Recipient : Valeo Pharma
Deal Size : Undisclosed
Deal Type : Licensing Agreement

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Epinephrine
Therapeutic Area : Immunology
Study Phase : Approved FDF
Sponsor : Pan Canadian Pharmaceutical Alliance
Deal Size : Undisclosed
Deal Type : Agreement
Details : Kaléo has completed negotiations with the pan Canadian Pharmaceutical Alliance (pCPA) for a Letter of Intent regarding ALLERJECT® (epinephrine injection, USP) auto-injector for the treatment of serious allergic reactions.
Product Name : Allerject
Product Type : Hormone
Upfront Cash : Undisclosed
August 10, 2020
Lead Product(s) : Epinephrine
Therapeutic Area : Immunology
Highest Development Status : Approved FDF
Sponsor : Pan Canadian Pharmaceutical Alliance
Deal Size : Undisclosed
Deal Type : Agreement

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Fluticasone Propionate
Therapeutic Area : Otolaryngology (Ear, Nose, Throat)
Study Phase : Approved FDF
Sponsor : Optinose
Deal Size : Undisclosed
Deal Type : Agreement
Optinose Announces XHANCE Co-Promotion Agreement with Kaléo
Details : Under the terms of the agreement, kaléo will promote XHANCE to an agreed-upon audience of office-based healthcare professionals, rapidly increasing promotional reach and frequency.
Product Name : Xhance
Product Type : Steroid
Upfront Cash : Undisclosed
July 08, 2020
Lead Product(s) : Fluticasone Propionate
Therapeutic Area : Otolaryngology (Ear, Nose, Throat)
Highest Development Status : Approved FDF
Sponsor : Optinose
Deal Size : Undisclosed
Deal Type : Agreement
